Filter Results:
(3,422)
Show Results For
- All HBS Web
(3,422)
- People (9)
- News (721)
- Research (2,192)
- Events (38)
- Multimedia (28)
- Faculty Publications (1,298)
Show Results For
- All HBS Web
(3,422)
- People (9)
- News (721)
- Research (2,192)
- Events (38)
- Multimedia (28)
- Faculty Publications (1,298)
- 15 Sep 2003
- Research & Ideas
The Lessons of New-Market Disruption
Teradyne: Testing Opportunity In 1994, Teradyne, a leading provider of machines that test the quality of microprocessors and other integrated circuits as they come off the assembly line, saw an opportunity... View Details
- 25 Apr 2014
- News
To create breakthrough strategies, harness creativity to the scientific method
rigorous analysis tests them." Rivkin and collaborators A. G. Lafley, Roger Martin, and Nicolaj Siggelkow, recommend combining creativity with the scientific method in an approach where a team representing diverse specialties,... View Details
- Web
Frequently Asked Questions | MBA
submission of an English Language test (TOEFL, IELTS, PTE, or Duolingo) satisfy the writing assessment requirement? I studied at a university where the sole language of instruction was English. May I submit an English Language View Details
- 2023
- Working Paper
Market Exclusivity and Innovation: Evidence From Antibiotics
By: Edward Kong and Olivia Zhao
The US incentivizes drug innovation via patents as well as market exclusivity periods awarded by the US Food and Drug Administration. We estimate the causal effects of extending market exclusivity for an important drug class: antibiotics. Using a... View Details
Keywords: Health Testing and Trials; Innovation and Invention; Motivation and Incentives; Government Administration; Government Legislation; Pharmaceutical Industry; United States
Kong, Edward, and Olivia Zhao. "Market Exclusivity and Innovation: Evidence From Antibiotics." Working Paper, December 2023.
- 23 Jul 2008
- Sharpening Your Skills
Sharpening Your Skills: Balanced Scorecard in Action
reduce the gap between strategy and execution? Does the BSC work in testing strategy? How Can The Balanced Scorecard Improve Corporate Governance? Working Paper: Improving Corporate Governance with the Balanced Scorecard The authors... View Details
- February 2022 (Revised November 2022)
- Case
Nuritas
By: Mitchell Weiss, Satish Tadikonda, Vincent Dessain and Emer Moloney
Nora Khaldi had built a technology “to unlock the power of nature” in the service of extending human lifespan and improving health, and now in April 2020 was debating telling her Board of Directors she wanted to put on ice some of her discoveries. Nuritas, the company... View Details
Keywords: Cash Burn; Cash Flow Analysis; Pharmaceutical Companies; Founder; Artificial Intelligence; AI; Entrepreneurship; Health Testing and Trials; Health Care and Treatment; Decision Making; Market Entry and Exit; AI and Machine Learning; Pharmaceutical Industry
Weiss, Mitchell, Satish Tadikonda, Vincent Dessain, and Emer Moloney. "Nuritas." Harvard Business School Case 822-080, February 2022. (Revised November 2022.)
- 01 Mar 2016
- News
Off Script
(Thinkstock) Prescription drug spending increased by more than 13 percent in the United States in 2014, raising health insurance premiums and the ire of consumers and politicians. The reasons behind the rise are many, including the high cost of drug development—as much... View Details
- Web
Reapplicants | MBA
to complete the current application in its entirety. A valid Graduate Management Admission Test (GMAT) or Graduate Record Examination (GRE) is a prerequisite for admission; the GMAT or GRE test needs to be... View Details
- Mar 2012
- Article
Rethinking School
Economists have found that the higher a country's academic test scores, the faster its GDP grows. That puts the United States' perennially mediocre test scores in a particularly ominous light. Progress is... View Details
- 24 Mar 2020
- Research & Ideas
These Coronavirus Heroes Show Us How Crisis Leadership Works
Schinecker, CEO of Roche Diagnostics, leads a company that received the FDA’s first emergency use authorization for a commercially developed COVID-19 test on March 13. Roche now believes it can ship up to 400,000 View Details
- 19 Aug 2016
- News
Lending a Hand to Small Businesses in Emerging Markets
In emerging markets, where traditional credit scores are rare, how can lenders decide who is creditworthy? Just ask, says DJ DiDonna (MBA 2010), cofounder and chief strategy officer of the for-profit Entrepreneurial Finance Lab. The company has developed a 20- to... View Details
- Web
Research in Black and White | Baker Library
Research in Black and White Photo: Meroe Morse, test photograph, August 1959. Polaroid Corporation Records Related to Meroe Morse, b. VII.83, f. 15. In 1948, only a few years after starting at Polaroid, Meroë Morse became the laboratory... View Details
- Profile
Eric Sonnier
industries, including oil, telecom, and retail. Then Eric became interested in entrepreneurship. “I wasn’t sure it was right for me, but you don’t know until you test it,” Eric says. “I went from the largest professional-services company... View Details
- January 2023
- Case
Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery
By: Regina Herzlinger and Brian Walker
What should a successful executive (HBS Baker Scholar) assess as her next move as the CEO of a firm with a promising and yet uncertain new drug? Amy Burroughs’ mandate to successfully commercialize Cleave Therapeutics’ drug for a cancer with no current successful... View Details
Keywords: Product Development; Leadership; Health Testing and Trials; Research and Development; Risk and Uncertainty; Financial Condition; Partners and Partnerships; Pharmaceutical Industry
Herzlinger, Regina, and Brian Walker. "Cleave Therapeutics: Taking a Risk on Oncology Drug Discovery." Harvard Business School Case 323-045, January 2023.
- February 2009
- Case
Avid Radiopharmaceuticals: The Venture Debt Question
By: Matthew Rhodes-Kropf and Ann Leamon
The CEO of a promising biotech company must decide how to respond to the macro-economic slump of late 2008. He had planned to pursue an aggressive schedule, moving the firm's Alzheimer's and Parkinson's disease imaging compounds through clinical trials and into the... View Details
Keywords: Financial Crisis; Entrepreneurship; Borrowing and Debt; Venture Capital; Financial Management; Investment; Health Testing and Trials; Expansion; Biotechnology Industry; Pharmaceutical Industry
Rhodes-Kropf, Matthew, and Ann Leamon. "Avid Radiopharmaceuticals: The Venture Debt Question." Harvard Business School Case 809-086, February 2009.
- 01 Dec 2011
- News
Research With Impact: Changing Global Health Practices
Professor Ashraf (center) with members of the study implementation team at Chipata Clinic, Lusaka, Zambia, including fi eld managers, surveyors, community health workers, and a study nurse. (click for larger view) Read a summary of Ashraf's recent presentation at HBS... View Details
- February 2020
- Teaching Note
Theranos: Who Has Blood on Their Hands? (A) and (B)
By: Nien-he Hsieh and Christina R. Wing
Teaching Note for HBS Nos. 619-039 and 320-091. View Details
- November 2009 (Revised March 2010)
- Case
Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story
By: Richard G. Hamermesh, Raju Kucherlapati and Rachel Gordon
In May 2007, Amgen Inc. (Amgen) received disappointing news from the European Medicines Agency (EMEA) that its drug Vectibix, developed to fight metastatic colorectal cancer, had been rejected. This was especially surprising news given that a similar rival drug had... View Details
Keywords: Entrepreneurship; Governing Rules, Regulations, and Reforms; Health Testing and Trials; Marketing Strategy; Product Positioning; Genetics; Biotechnology Industry; Europe; United States
Hamermesh, Richard G., Raju Kucherlapati, and Rachel Gordon. "Managing Drugs on the Forefront of Personalized Medicine: The Erbitux and Vectibix Story." Harvard Business School Case 810-066, November 2009. (Revised March 2010.)
- 11 Dec 2014
- News
Revolutionizing digital medical records
coordinated, and lower-cost care. Bushkin expects MedKaz to revolutionize health care, bringing about changes in care quality and facilitating changes in the way care is delivered. With it, doctors can avoid medical mistakes and unnecessary View Details
- 12 Nov 2015
- Research & Ideas
Can Consumers be Trusted with Their Own Health Care?
and a profile that varies by situation and according to the patient’s life stage.” Patient Empowerment Taken Too Far? As an example of patient empowerment—and a glimpse at its potential problems—Quelch talked about taking the 23andMe test, a saliva-based... View Details